Sugi Predict

Sugi Predict / Targets / KLK4

KLK4

Kallikrein-4 · Q9Y5K2 · KLK4 on Sugi Atlas →

992 patent compounds predicted against KLK4, 508 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9971041 SCHEMBL9971041 0.75 5/20
SCHEMBL5881673 SCHEMBL5881673 0.64 5/20
SCHEMBL2246988 SCHEMBL2246988 0.59 5/20
SCHEMBL16152335 SCHEMBL16152335 0.57 5/20
SCHEMBL1436662 SCHEMBL1436662 0.56 5/20
SCHEMBL9970972 SCHEMBL9970972 0.56 5/20
SCHEMBL10400079 SCHEMBL10400079 0.51 5/20
SCHEMBL7300806 SCHEMBL7300806 0.48 5/20
SCHEMBL7300801 SCHEMBL7300801 0.48 5/20
SCHEMBL2249449 SCHEMBL2249449 0.41 5/20
SCHEMBL12354626 SCHEMBL12354626 0.81 4/20
SCHEMBL2249441 SCHEMBL2249441 0.76 4/20
SCHEMBL17126273 SCHEMBL17126273 0.71 4/20
SCHEMBL9856806 SCHEMBL9856806 0.70 4/20
SCHEMBL3394756 SCHEMBL3394756 0.63 4/20
SCHEMBL9971039 SCHEMBL9971039 0.63 4/20
SCHEMBL2242610 SCHEMBL2242610 0.62 4/20
SCHEMBL12088090 SCHEMBL12088090 0.62 4/20
SCHEMBL5689257 SCHEMBL5689257 0.58 4/20
SCHEMBL19614989 SCHEMBL19614989 0.57 4/20

Clinical trials — most relevant to KLK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer PHASE2COMPLETED
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer PHASE2COMPLETED
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA PHASE1/PHASE2RECRUITING
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer PHASE2COMPLETED
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery PHASE1/PHASE2COMPLETED
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. PHASE2WITHDRAWN
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer PHASE2COMPLETED
Cilengitide in Treating Patients With Prostate Cancer PHASE2COMPLETED
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy PHASE2RECRUITING
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) PHASE2COMPLETED
Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3] PHASE1/PHASE2COMPLETED
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy PHASE2RECRUITING
Enzalutamide + External Beam Rt For Prostate PHASE2COMPLETED
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma PHASE2COMPLETED
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21 PHASE1COMPLETED
A Phase I Clinical Study of a Single Dose of KLA480 PHASE1RECRUITING
Study to Assess PK, Safety and Tolerability in Healthy Subjects PHASE1COMPLETED
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients. PHASE1COMPLETED
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer PHASE1COMPLETED
A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer PHASE1COMPLETED
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents PHASE1SUSPENDED
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population nanRECRUITING
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen) nanENROLLING_BY_INVITATION
Predicting Prostate Biopsy Results With Biomarkers and mpMRI. nanCOMPLETED
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer nanCOMPLETED
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia nanCOMPLETED
The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment nanCOMPLETED
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy nanCOMPLETED
Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KLK4 binder may also engage these)

ProteinNameSimilarity
Q9Z0M1 — 0.986 Q9Z0M1 →
Q9UBX7 — 0.933 Q9UBX7 →
Q9QYN3 — 0.928 Q9QYN3 →
KLK14 Kallikrein-14 0.925 landscape →
KLK8 Kallikrein-8 0.925 landscape →
PRTN3 Myeloblastin 0.921 landscape →
P79204 — 0.912 P79204 →
Q61096 — 0.912 Q61096 →
Q61955 — 0.910 Q61955 →
O46683 — 0.907 O46683 →
KLK5 Kallikrein-5 0.906 landscape →
P20718 — 0.906 P20718 →
P80931 — 0.904 P80931 →
P21842 — 0.903 P21842 →
P56435 — 0.903 P56435 →
CMA1 Chymase 0.902 landscape →
P52195 — 0.897 P52195 →
Q9H2R5 — 0.896 Q9H2R5 →
P19236 — 0.894 P19236 →
P80219 — 0.894 P80219 →
GZMB Granzyme B 0.893 landscape →
P51124 — 0.892 P51124 →
O88780 — 0.892 O88780 →
Q7JIG6 — 0.892 Q7JIG6 →
KLK2 Kallikrein-2 0.891 landscape →
CTSG Cathepsin G 0.889 landscape →
KLK7 Kallikrein-7 0.888 landscape →
A7WPL7 — 0.886 A7WPL7 →
P17977 — 0.886 P17977 →
Q07276 — 0.884 Q07276 →